Intranasal Midazolam in Children as a Pre-Operative Sedative

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam easier and more comfortable without affecting how the midazolam works as a sedative.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED

NCT05934669

Laceration of Skin Anxiety Discharge Time

RECRUITING PHASE4

Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children

NCT04586504

Procedural Anxiety

COMPLETED PHASE1/PHASE2

Combination With Intranasal Dexmedetomidine and Oral Midazolam for Premedication in Pediatric Patients

NCT04135014

Anxiety

UNKNOWN PHASE4

Premedication With Intranasal Dexmedetomidine or Midazolam for Prevention of Emergence Agitation in Children

NCT03171740

Emergence Delirium

COMPLETED PHASE3

Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam

NCT02192710

Paediatric Outpatient Surgery

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Midazolam is often given before surgery to sedate a patient before anesthesia is given. Children are often given a small dose either by mouth or squirted into the nose. Children will often spit out the oral midazolam, making it difficult to know how much medicine, if any, they have received. Giving midazolam into the nose is more reliable, but children may complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also occur when midazolam is squirted alone into the nose. The purpose of this study is to see if adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam easier and more comfortable without affecting how the midazolam works as a sedative.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sedation, Conscious

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline placebo

saline placebo

Group Type PLACEBO_COMPARATOR

saline placebo

Intervention Type DRUG

Placebo - Control patients will receive intranasal saline.

Nasal Midazolam only

Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam

Group Type ACTIVE_COMPARATOR

Midazolam

Intervention Type DRUG

Study participants will be randomly assigned to one of three treatment groups:

* Group 1 - Placebo - Control patients will receive intranasal saline.
* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Midazolam and Xylocaine

Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam

Group Type ACTIVE_COMPARATOR

Midazolam

Intervention Type DRUG

Study participants will be randomly assigned to one of three treatment groups:

* Group 1 - Placebo - Control patients will receive intranasal saline.
* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

xylocaine

Intervention Type DRUG

Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Midazolam

Study participants will be randomly assigned to one of three treatment groups:

* Group 1 - Placebo - Control patients will receive intranasal saline.
* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Intervention Type DRUG

xylocaine

Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.

Intervention Type DRUG

saline placebo

Placebo - Control patients will receive intranasal saline.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

versed

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children aged 18 months-7 years, scheduled for a minor otolaryngology (ENT) surgical procedure requiring mask anesthesia
2. American Society of Anesthesiologists (ASA) Class 1 or 2
3. Parent willing and able to provide written informed consent
4. Parent willing and able to complete the OBD VAS

Exclusion Criteria

1. ASA Class 3 or greater
2. History of allergy to midazolam or xylocaine
3. Presence of acute respiratory infection at time of surgery
4. Parent unwilling or unable to provide informed consent
5. Parent unwilling or unable to complete the OBD VAS

Minimum Eligible Age

18 Months

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No